Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?

Abstract

Serena Maria Boccia,1,* Carolina Maria Sassu,1,* Raffaella Ergasti,1 Laura Vertechy,1 Adriana Ionelia Apostol,2 Eleonora Palluzzi,1 Anna Fagotti,1,2 Giovanni Scambia,1,2 Claudia Marchetti1,2 1Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, 00136, Italy; 2Dipartimento Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, 00136, Italy*These authors contributed equally to this workCorrespondence: Claudia Marchetti, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, 00136, Italy, Email [email protected]: In the era of single and combination maintenance therapies as well as platinum and Poly (ADP-ribose) polymerase inhibitors (PARPi) resistance, the choice of subsequent treatments following first-line platinum-based chemotherapy in recurrent ovarian cancer (ROC) patients has become increasingly complex. Within the ovarian cancer treatment algorithm, particularly in the emerging context of PARPi resistance, the role of trabectedin, in combination with pegylated liposomal doxorubicin (PLD) still preserves its significance. This paper offers valuable insights into the multifaceted role and mechanism of action of trabectedin in ROC. The main results of clinical trials and studies involving trabectedin/PLD, along with hints of Breast Cancer genes (BRCA)-mutated and BRCAness phenotype cases, are critically discussed. Moreover, this review provides and contextualizes potential scenarios of administering trabectedin in combination with PLD in ROC, according to established guidelines and beyond.Keywords: ovarian cancer, trabectedin, platinum eligibility

Keywords

• ovarian cancer
• trabectedin
• platinum eligibility.